TrialHaematologica2013

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.

Meletios A Dimopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.